PharmAbcine Publishes Study in Science Advances Demonstrating the Potential of PMC-403 in Preclinical Models of Idiopathic Systemic Capillary Leak SyndromeAdvertisementStudy reveals a promising avenue for addressing Idiopathic Systemic Capillary Leak Syndrome (ISCLS, a.k.a. The results underscore the novel mechanism of action, demonstrating the ability of PMC-403 to reduce vascular leakage associated with ISCLS in the preclinical models. The paper, titled “A ligand-independent Tie2-activating antibody reduces vascular leakage in models of Clarkson Disease” highlights the significance of Tie2 activation and its potential implications for the treatment of ISCLS. In February 2023, the US FDA granted Orphan Drug Designation (ODD) for PMC-403 for the treatment of Systemic Capillary Leak Syndrome. Dr. Jin-San Yoo, President & CEO of PharmAbcine, commented “This study provides vital insights into the efficacy and potential expandability of Tie2-activating antibody for vascular diseases.
